Baxter International

Baxter International Inc. is a global healthcare company that develops, manufactures, and markets products and therapies for hospitals, clinics, and home care settings. Its portfolio includes intravenous solutions, drug delivery systems, renal dialysis equipment and therapies, parenteral nutrition, biosurgery agents, and advanced surgical tools. The company serves patients with conditions such as kidney disease, hemophilia, immune disorders, infectious diseases, and critical illnesses. Baxter’s offerings are designed to support medication administration, fluid management, and nutritional support across diverse care environments.

The corporation is headquartered in Deerfield, Illinois, United States of America, and was founded in 1931. Baxter International trades on the New York Stock Exchange under the ticker symbol BAX and maintains a workforce described as tens of thousands of employees worldwide. It reports an operational presence in more than 100 countries, supplying its products to both public and private health systems. This geographic reach enables the company to address regional health needs while adhering to local regulatory frameworks.

Baxter distinguishes itself through a longstanding focus on renal care, providing dialysis machines, consumables, and related services that support patients with acute and chronic kidney failure. The company also emphasizes medication delivery technologies, including infusion pumps and smart IV systems, aimed at improving safety and precision in drug administration. In addition, Baxter’s biosurgery portfolio offers sealants, hemostats, and tissue adhesives used in surgical procedures to reduce bleeding and promote healing. These competencies have positioned Baxter as a key supplier in critical care, nutrition, and surgery markets within the broader medical technology sector.

Structurally, Baxter International Inc. operates as a publicly traded corporation with several wholly owned subsidiaries, most notably Baxter Healthcare Corporation, which handles many of its commercial operations. The company previously separated its biopharmaceuticals business into an independent entity named Baxalta, which later merged with Shire, allowing Baxter to concentrate on its medtech and renal care divisions. Ownership remains dispersed among public shareholders, and the firm continues to pursue growth through product innovation, strategic partnerships, and geographic expansion while complying with the regulatory requirements of the jurisdictions in which it operates.